Hydrochlorothiazide / Triamterene Dosage

Medically reviewed by Drugs.com. Last updated on Aug 4, 2023.

Applies to the following strengths: 50 mg-75 mg; 25 mg-37.5 mg; 25 mg-50 mg

Usual Adult Dose for Edema

Hydrochlorothiazide 25 to 50 mg-Triamterene 37.5 to 100 mg orally once a day

Comments:

Patients who become hypokalemic on 50 mg of hydrochlorothiazide may be transferred directly to hydrochlorothiazide 50 mg-triamterene 75 mg orally once a day. Patients who become hypokalemic on 25 mg of hydrochlorothiazide may be transferred directly to hydrochlorothiazide 25 mg-triamterene 37.5 mg orally once a day.
Patients in whom hypokalemia cannot be risked may be initiated on hydrochlorothiazide 25 mg-triamterene 37.5 mg orally once a day.

Uses:

Treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone.
Initial therapy of hypertension or edema for patients in whom hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations or with a history of cardiac arrhythmias, etc.).

Hydrochlorothiazide 25 to 50 mg-Triamterene 37.5 to 100 mg orally once a day

Comments:

Patients who become hypokalemic on 50 mg of hydrochlorothiazide may be transferred directly to hydrochlorothiazide 50 mg-triamterene 75 mg orally once a day. Patients who become hypokalemic on 25 mg of hydrochlorothiazide may be transferred directly to hydrochlorothiazide 25 mg-triamterene 37.5 mg orally once a day.
Patients in whom hypokalemia cannot be risked may be initiated on hydrochlorothiazide 25 mg-triamterene 37.5 mg orally once a day.

Uses:

Treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone.
Initial therapy of hypertension or edema for patients in whom hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations or with a history of cardiac arrhythmias, etc.).

Contraindicated in patients with anuria, acute and chronic renal insufficiency, or significant renal impairment.

Use with caution

US BOXED WARNING:

HYPERKALEMIA: Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/L) can occur with all potassium-conserving diuretic combinations, including this product. Hyperkalemia is more likely to occur in patients with renal impairment, diabetes (even without evidence of renal impairment), or elderly or severely ill patients. Since uncorrected hyperkalemia may be fatal, serum potassium levels must be monitored at frequent intervals especially during initiation or dose changes of this drug or with any illness that may influence renal function.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.